Jonas joined Novo A/S in August 2014 as Investment Associate in Novo Large Investments. He assists in evaluating potential investment opportunities, as well as in the general management of M&A processes in the Large Investments area.
Jonas holds a BSc in International Business and an MSc in Applied Economics and Finance from the Copenhagen Business School.
Prior to joining Novo A/S, Jonas was employed with FIH Partners as an associate in M&A advisory. During this time, Jonas obtained a thorough understanding of M&A processes including valuation, financial modelling, due diligence, and industry analysis.
Sibel joined Novo A/S in September 2016 as an Associate in Novo Large Investments. She participates in deal sourcing and execution as well as in managing and developing the growing portfolio of investments.
Prior to joining Novo A/S, Sibel worked as a management consultant with Bain & Company in Copenhagen. During this time, she worked primarily with PE due diligences and post-acquisition projects for portfolio companies, as well as Corporate Strategy for large Nordic companies. Before this, Sibel worked as an Associate Consultant for Dalberg Global Development Advisors in their Copenhagen and New York offices.
Sibel holds a BSc in International Business & Politics and a MSc in Finance & Strategic Management from Copenhagen Business School.
Tiba joined Novo Ventures (US) Inc. in San Francisco, California in 2010. She is a member of the Board of Directors of AnaptysBio Inc., Arcellx Inc., Nkarta, Inc., Cianna Medical Inc., iRhythm Technologies Inc., Battersea, and Spruce Biosciences. Previously, she was a board member of Thesan Pharmaceuticals Inc. Tiba has more than 10 years of combined research and banking experience in life sciences that spans various therapeutic areas and technology platforms. Prior to joining Novo Ventures (US) Inc., Tiba was a Director with Burrill & Company where she has completed regional and cross-border M&A, licensing, and financing transactions for biotech and large pharmaceutical companies.
Tiba received her PhD from the Graduate Group in Biophysics at the University of California, San Francisco where her research involved developing computational methods for drug discovery. She has an undergraduate degree in physics from the University of California, Irvine. Tiba is also a published author of scientific articles and book chapters in the area of rational drug design.
Nis joined Novo A/S in February 2016 as a Business Associate in Novo Large Investments. He participates in deal sourcing and execution as well as in managing and developing the growing portfolio of investments.
Prior to joining Novo, Nis was a Consultant with the Boston Consulting Group in their Copenhagen office. During his time with BCG, Nis worked primarily with Corporate Development and Strategy.
Nis holds a BSc in International Business and an MSc in Finance and Accounting from the Copenhagen Business School.
Scott joined Novo Ventures (US) Inc. in San Francisco, California in 2012. Previously, he was a board member of Aerocrine AB.
From 2009-2012, Scott was part of Novo A/S’ Growth Equity team. Prior to joining Novo A/S he was a Managing Director at JP Morgan in San Francisco, heading the firm's West Coast biopharmaceuticals effort. Previous to that, Scott led Piper Jaffray's US biopharmaceuticals investment banking practice and was a member of the Health Care Group at Montgomery Securities. During his tenure as an investment banker, Scott originated and executed numerous transactions.
Scott holds an MBA from UCLA's Anderson Graduate School of Management and a BS from Colorado State University.
Peter joined Novo Ventures (US), Inc. in San Francisco, California in 2009, and in Boston, Massachusetts in 2015. He is on the Board of Directors of Ra Pharmaceuticals Inc. (NASDAQ: RARX) and HTG Molecular Diagnostics Inc. (NASDAQ:HTG), both publicly listed companies, and a number of privately held companies (see below). Previously, he was a board member of Nevro (NYSE: NVRO), Otonomy (NASDAQ: OTIC) and Alder (NASDAQ: ALDR), among others.
From 2001-2009, Peter was employed with Novo A/S as a partner in Novo Ventures. Prior to joining Novo A/S he was with McKinsey & Co. as a general consultant and as a specialist within the Scandinavian Corporate Finance and Strategy Group. At McKinsey, Peter focused on strategy development, mergers, acquisitions and alliances in various industries. He has BSc and MSc in Engineering from the Technical University of Denmark, and a post graduate degree in Mathematical Modelling in Economics by the European Consortium for Mathematics in the Industry.
Johan joined Novo A/S in April 2008 as Investment Director in Novo Finance. He is responsible for financial investments including strategic asset allocation and manager selection as well as liquidity management and handling of foreign exchange transactions.
Johan received his MSc in Finance from the Copenhagen Business School in 2003.
Prior to joining Novo A/S, Johan was employed with Scandium Asset Management for three years, and before that with Finansbanken A/S. During this time, Johan obtained a thorough understanding of financial markets including asset allocation, manager selection and investments in stocks, bonds and hedge funds.
Ray joined Novo Ventures (US) Inc. in Boston, Massachusetts in 2015.
He has over 10 years of research and business development experience, with expertise in biochemistry, molecular biology, and genetics. Ray was an associate at the Harvard University Office of Technology Development where he worked to commercialize technologies developed in both Chemistry and Stem Cell/Regenerative Biology. Ray completed a National Institute of Health (NIH) post-doctoral training fellowship at Harvard University while concurrently holding a business development position at Partners Healthcare Research Ventures and Licensing.
Ray was a pre-doctoral fellow at the Stowers Institute for Medical Research in Kansas City, Missouri. He holds a PhD from the University of Kansas in biochemistry and molecular biology, and a BS in biological sciences from the University of California Santa Barbara.
Stephan joined Novo A/S in September 2007 as Investment Director of Novo Seeds.
Stephan obtained his MSc degree from the Technical University of Denmark in 1988 and his PhD degree in 1992 from the Technical University of Denmark, for a project in diabetes immunology, conducted at Hagedorn Research Institute and University of California, San Francisco.
Prior to joining Novo Seeds, Stephan was Executive Vice President and Chief Operating Officer at Osteologix where he played a leading role in the development of the company, taking the lead candidate drug through all stages from lead identification to Phase II testing for osteoporosis treatment. He also played an active role in the company’s financing including a public listing in the USA on the OTC exchange through a reverse merger with a public shell company. Previously Stephan has worked in the metabolic bone disease and arthritis areas in Nordic Bioscience and Osteometer Biotech and as a protein chemist in Novo Nordisk A/S.
Stephan serves on the Board of Directors of Acesion Pharma, Forendo Pharma OY, Galecto Biotech AB, Heparegenix GmbH, IO Biotech and Lysogene SA. He also serves as chairman for VentureCup, a non-profit entrepreneurship organization.
Christian joined Novo A/S in August 2016 as Financial Controller in Novo Finance.
Prior to joining Novo A/S Christian was employed at PricewaterhouseCoopers (PwC) for seven years as an auditor. At PwC Christian had the title of Manager and was responsible for the statutory audit of a broad selection of clients as well as delivering associated tax and accounting services.
Christian holds an MSc in Business, Economics and Auditing from Copenhagen Business School.
Emmanuelle joined Novo A/S in September 2015 as Investment Director of Novo Seeds. She led the Series B investments in Corwave, and serves on the Boards of Adenium Biotech, Avilex Pharma, Corwave, Inthera Bioscience, MinervaX and Pcovery.
Emmanuelle has close to 10 years of experience in venture capital investment. Prior joining Novo Seeds, Emmanuelle was Partner Life Sciences at Auriga Partners, where she was in charge of seed stage investments for Auriga IV Bioseeds, a seed fund dedicated to projects related to infectiology and microbiology. From 2007 until 2014, she was part of Omnes capital (formerly Crédit Agricole Private Equity) life sciences team with multiple portfolio companies leading to successful exits or IPOs. She was also in charge of the Seed Stage Investment Program and actively invested and sat on the board of directors of several companies in Belgium and The Netherlands.
Emmanuelle obtained her MSc degree from the Agrocampus Ouest (France) in 2003 and her PhD degree in 2006 from the Paris 7 University, for her work on the immunosuppressive properties of a bacterial toxin, conducted at Pasteur Institute (Paris, France). She also has a Specialized Master in pharmaceutical management from ESCP-EAP.
Thomas joined Novo A/S in 2000. He is a member of the Boards of Directors of Galera Therapeutics, Inc., Nuvelution Pharma, Inc., Ophthotech Corporation and PanOptica Inc.
Thomas held research positions at the Hagedorn Research Institute, Denmark, and at the Scripps Research Institute, La Jolla, USA. In 1990, he joined Novo Nordisk A/S, initially working in Health Care Discovery on various aspects of diabetes immunology and pathogenesis, and from 1996 in Health Care Clinical Drug Development.
Thomas obtained an MD degree from the University of Copenhagen in 1981 and a DMSc degree, also from the University of Copenhagen in 1986.
Morten joined Novo Seeds in 2016 as Investment Director. He serves on the Board of Hoba Therapeutics, Merozyne Therapeutics and NMD Pharma.
Prior to joining Novo, Morten was Director of Corporate Development at H. Lundbeck A/S where he was involved in M&A, corporate strategy, BD&L, portfolio management and equity investments. While at Lundbeck Morten successfully led the acquisition of orphan neurology company Chelsea Therapeutics for 658 USD m and was involved in a range of other deals including the 1.8 USD Bn alliance with Otsuka Pharmaceuticals as well as equity investments and spinouts. Before Lundbeck, Morten worked as commercial manager in technology transfer to commercialize and establish new companies in biotech and medtech. Earlier in his career, Morten co-led the life science consulting practice at a boutique advisory firm in Copenhagen focusing on business development and management consulting.
Morten holds an MSc in Human Biology from the University of Copenhagen.
Dr Edwards joined Novo A/S in 2003 working out of the UK. He is chairman of the Board of Directors of Epsilon-3 Bio Ltd., and Vantia Therapeutics Ltd., and a member of the Board of Directors of Acacia Pharma Ltd., Karus Therapeutics Ltd., Nuvelution Pharma, Inc., Tarsa Therapeutics Inc., Verona Pharma and F2G. Dr Edwards also holds an adjunct professorship at Copenhagen Business School (CBS SIMI).
From 1998-2003, Dr Edwards was the CEO of ReNeuron Holdings, taking that company public in 2000 and raising a total of £25m in equity and debt financing. From 1994-1998, he was Corporate V.P and Head of Drug Development for Novo Nordisk A/S where he was responsible for all aspects of pre-clinical and clinical drug development. Previously, he worked for six years in the USA first as V.P Pharmacology and Medical Affairs of ZymoGenetics Inc. in Seattle, and then as Senior V.P for Medical Affairs at Novo Nordisk in Princeton NJ.
Dr Edwards trained in physiology and medicine in Manchester. He is a Member of the Royal Colleges of Physicians, a Member with distinction of the Royal College of General Practitioners, a Fellow of the Faculty of Pharmaceutical Medicine and holds an MBA from the University of Warwick.
Aleks joined Novo A/S in September 2014 as Asset Director in Novo Large Investments taking part in managing and developing the growing portfolio of investments.
Prior to joining Novo, Aleks was employed as Vice President in Baxter International in Illinois and Shanghai, working with global M&A licensing, growth strategies, investment prioritization and go-to-market planning. Other previous employments include Pfizer Global Research and Development, Thomson Scientific & Healthcare and McKinsey & Company (all U.S.A.).
Aleks holds a Ph.D. in Biochemical Engineering (1999) and a M.Sc. in Chemical Engineering Practice (1995) from Massachusetts Institute of Technology.
Aleks is a member of the board of directors of Symphogen A/S and Xellia Pharmaceuticals ApS.
Shawna joined Novo Ventures (US) Inc., San Francisco, California in 2015.
Previously, she served as Executive Director of Business Development at VxP Pharma, a service company facilitating contractual collaborations in discovery, development, and manufacturing in the life science industry. In addition, Shawna was Co-Founder and Scientific Advisor of a Bay Area startup developing platform technology relevant to neurological and ocular indications. Her research experience spans the areas of cellular physiology and molecular engineering with applications to biological therapeutics and gene therapy.
Shawna received her PhD in Biochemistry & Molecular Biophysics with an emphasis in Neuroscience from the California Institute of Technology (Caltech). Prior to she earned combined BS and Master’s degrees from Kansas State University in Biochemistry in an accelerated 5 year program.
Danielle joined Novo Ventures (US) Inc. in San Francisco, California in 2017 as Venture Coordinator. She assists with the administration and support for the San Francisco office of Novo Ventures (US) Inc.
Danielle received a Bachelor of Arts degree from San Francisco State University. Before joining Novo Ventures (US) Inc., she worked for a capital management firm, providing project and administrative support to the CEO and other members of the firm’s executive management team.
Jonas joined Novo A/S in December 2015 as Associate General Counsel and takes part in handling all legal matters within the company, including in particular investments and divestments, corporate law and general contract matters.
Prior to joining Novo A/S, Jonas was employed with Danske Bank A/S for two years where he was globally responsible for the legal aspects of the bank’s corporate finance activities in the Nordics, the UK and the US. During the eight years before that, Jonas worked as senior associate in the M&A and capital markets group at the law firm Plesner in Copenhagen and as foreign lawyer in the corporate finance group at the law firm Reed Smith in New York. As a result, Jonas has obtained significant experience with respect to Danish, Nordic and international M&A, capital markets and financing transactions.
Jonas holds a Master of Laws from the University of Copenhagen (2005) and an LL.M. with honors from Columbia Law School (2010) with focus on corporate finance, securities regulation and M&A. He is a member of the Danish Bar Association
Peter joined Novo A/S in November 2016 as Chief Financial Officer and member of the Management Board with responsibility for Finance, Legal, Valuation and IT. He holds an MSc in Finance and Accounting from Aarhus Business School, Denmark as well as an EMBA from IMD, Switzerland.
Prior to joining Novo A/S, Peter has been employed for 16 years with Novo Nordisk in various leadership position in Denmark and internationally and before this 5 years as equity analyst in various financial institutions.
Henrik joined Novo A/S in January 2017 as a Senior Director, Novo Large Investments, leading investment process and taking part in managing and developing the growing portfolio of investments. Prior to joining Novo A/S, Henrik was employed as a Senior Vice President in Moelis & Co. in London, focusing on healthcare buy-and sell-side M&A transactions. Other previous employments include Deutsche Bank and ABN AMRO all in London.
Henrik holds a BSc. in Business Administration and an MSc. in Applied Economic and Finance from the Copenhagen Business School.
Ken joined Novo Ventures (US) Inc. in San Francisco, California in 2015.
Ken brings experience as a Senior Market Planning Manager at Genentech, where he helped guide strategic decision making for the Ophthalmology and HER2 franchises. Prior to Genentech, Ken worked as a management consultant at L.E.K. Consulting and as the Entrepreneurship Program Manager at QB3/Mission Bay Capital, where he helped create new programs to launch and support life sciences companies in the Bay Area.
Ken studied cellular lipid storage and metabolism as an A.P. Giannini Foundation Fellow at the J. David Gladstone Institutes, earned a PhD in Pharmacology from Yale University, and has a BS in Molecular Biology from Texas Tech University, where he was a Howard Hughes Medical Institute undergraduate research fellow.
Mette joined Novo A/S in August 2016 as HR Senior Specialist in People & Organisation. She is responsible of organisation and employee development, P&O projects, sparring and support to employees, recruitment, climate surveys, P&O processes, systems and tools.
Prior to joining Novo A/S, Mette played different roles in Danske Bank Group within banking, investment, different Human Resource areas and latest she held a position as HR Partner at Danica Pension.
Annemette joined Novo Seeds in June 2015. She is responsible for the coordination of the overall activities and administration in Novo Seeds.
Prior to joining Novo, Annemette was employed at Ferring Pharmaceuticals in various administrative roles with responsibility for budgets, insurances, project management support and coordination of meetings and events. Most recently she was Process & Systems Manager, responsible for the Clinical Trial Management system.
Annemette holds a MSc in International Marketing and Management from Copenhagen Business School.
Kasper joined Novo A/S in October 2014 as a Business Associate and will be taking part in managing and developing the growing portfolio of investments.
Prior to joining Novo, Kasper was an Engagement Manager for McKinsey & Company in their Copenhagen Office. During his time with McKinsey & Co., Kasper primarily served pharmaceutical and medical device companies.
Kasper holds a Ph.D. in Nanoscience from Aarhus University (2011) and a M.Sc. in Nanoscience (2009) from Aarhus University.
Morten joined Novo A/S in March 2005 as Investment Director in Novo Finance. He is responsible for managing the financial investments including strategic and tactical asset allocation and manager selection.
Morten received his MSc in Finance from the Aarhus School of Business in 1997.
Prior to joining Novo A/S, Morten was employed with Novo Nordisk A/S’ Corporate Treasury for four years, and before that with Nordea Markets. During this time, Morten obtained a thorough understanding of the financial markets seen both from the financial and corporate sector, including macro-economic understanding, negotiation, trading, investment and M&A activities.
Amy joined Novo Ventures (US) Inc. in Boston, Massachusetts in 2015 as Venture Coordinator. She assists with the administration and support for the Boston office of Novo Ventures (US) Inc.
Amy received a Bachelor of Arts degree from Hobart and William Smith Colleges. Before joining Novo Ventures (US) Inc., she held various positions in healthcare administration, providing project and administrative support.
Simon Kold joined Novo A/S in January 2014 as student assistant during his Master's degree studies. In August 2015 he was appointed as Financial Analyst and is taking part in managing Novo's financial investments.
Mr Kold holds a M.Sc in Finance & Accounting from Copenhagen Business School. He also holds a BA in Theology from the University of Copenhagen.
Nilesh joined Novo Ventures (US) Inc. in Boston in 2015. Prior to joining Novo, Nilesh was Senior Director at MS Ventures where he invested in early stage life science companies. Nilesh led the initial investments and served on the Boards of Auxogyn, Canbex, f-Star, Raze Therapeutics, RaNA Therapeutics, Padlock Therapeutics and TocopheRx. In addition to his venture investment role, Nilesh has successfully led several strategic licensing transactions at Merck Serono in oncology and autoimmune therapeutic areas.
Nilesh received his PhD from the Department of Chemistry and Chemical Biology at Harvard University. He holds an MBA from Harvard University, and did his undergraduate degree in Natural Sciences from the University of Cambridge, UK.
Kasim Kutay was appointed CEO of Novo A/S on 1 September 2016.
Kasim Kutay holds a B.Sc. and M.Sc. in Economics from the LSE (London School of Economics). Prior to joining the Novo Group, Mr. Kutay spent seven years at Moelis & Co, a leading global independent investment bank. Prior to that, Mr. Kutay spent 18 years at Morgan Stanley. During his investment-banking career, Mr. Kutay was focused on the healthcare sector, where he advised companies on the full spectrum of corporate finance matters including mergers and acquisitions as well as equity and debt financings.
Jeni joined Novo Ventures (US) Inc. in Boston, MA in 2016.
Previously, Jeni supported the Director of Research at Aquilo Capital Management in San Francisco, CA, where she helped assess investment opportunities of small cap biotech companies. She also has experience in industry research, having interned in the Late Stage Product Research and Development group at Genentech. Jeni was a co-founder of ViVita Technologies, Inc., a cardiovascular-focused medtech startup with a platform to generate immune-compatible tissues from animal sources.
Jeni earned her PhD in Biomedical Engineering with a Designated Emphasis in Biotechnology from the University of California, Davis, where she studied functional cartilage tissue engineering. She received her BS in Bioengineering from the University of California, Berkeley.
Junie joined Novo Ventures (US) Inc., in 2016 in San Francisco, CA, as US General Counsel. She helps to manage investment structuring and negotiation, portfolio company management, regulatory governance, and other general legal matters.
Prior to joining Novo, Junie was Counsel at Wilson Sonsini Goodrich & Rosati where she represented private and public biotech and technology companies and venture capital firms in financings, mergers and acquisitions, corporate governance, recapitalizations and other stock related matters, complex contract negotiations, securities compliance and disclosures, employment issues, intellectual property issues, and strategic partnerships.
Junie holds a Juris Doctor from New York University School of Law, New York, New York, and a B.A. in Economics from Smith College, Northampton, Massachusetts.
Heather is responsible for controlling the venture investments from a financial and administrative perspective.
Prior to joining Novo A/S in 2003, Heather spent seven years with Brown Brothers Harriman & Co., first as head of the European Internal Audit function based in Luxembourg and then as the Investment Management Business Line Controller based in New York City. Prior to this, Heather was an Audit Manager and CPA with PricewaterhouseCoopers in both Luxembourg and Boston.
Heather holds a BS in Accounting and a BA in Business Administration from the University of Kansas.
Josefine was appointed Recruitment and Development Coordinator in June 2016. Josefine takes part in recruitments and development for Novo A/S and the Novo Nordisk Foundation and assists with HR functions.
Josefine joined Novo A/S in December 2014 as a student assistant during her studies. She holds a BSc and an MSc in business administration and psychology from Copenhagen Business School.
She spent the first four years with Novo A/S as part of the Seeds team, where she helped build a strong portfolio of seed and Series A stage companies, primarily in Scandinavia. She led the initial investments and served on the Boards of IO Biotech, MinervaX, and Pcovery, and as an Observer with Forendo and Galecto.
Nanna joined the Ventures team in 2016. She now serves on the Boards of Epsilon-3 Bio and Orphazyme.
From 2008-2012, Nanna was an Associate with Apposite Capital, a London-based venture fund, where she was part of the life science investment team and participated in both primary and secondary investments, with multiple portfolio companies leading to highly successful exits for the fund. Earlier in her career, she worked at Cancer Research UK as a research analyst, and as a consultant to various biotech and healthcare venture projects during her MBA.
Nanna received her PhD in Neuroscience from University College London as a Wellcome Trust Scholar. She holds an MBA with distinction from University of Cambridge, where she was a Sainsbury Scholar, and a 1st class BA from University of Oxford.
Max joined Novo A/S in November 2005 as Controller in Novo Finance. He is responsible for accounting and tax.
Max received his Graduate Diploma in Business Administration (Financial and Management Accounting) from Copenhagen Business School in 2000 and a MSc in Business Administration and Auditing from the Copenhagen Business School in 2005.
Prior to joining Novo A/S, Max was employed with Deloitte for 10 years. During this time, Max was responsible for the audit of a broad selection of clients and cases within audit, accounting and tax.
Peter joined Novo Ventures (US) Inc. in San Francisco, California in 2012. He is chairman of the Board of Directors of Allakos Inc., and a member of the Board of Directors of Corvus Pharmaceuticals Inc., Bolt Therapeutics, E-Scape Bio. Spruce Biosciences and Tioma Therapeutics. Previously, he was a board member of Cytochroma Inc., HemoFocus ApS, Neurokey A/S and Orphazyme ApS.
From 2009-2012, Peter was employed with Novo A/S as a partner in Novo Ventures. In 2004, Peter co-founded Curalogic A/S, served as CEO until 2009 and took the company public in 2006. From 2000-2004, he was Chief Operating Officer of 7TM Pharma A/S, which he also co-founded. Previously, he worked for 11 years with NeuroSearch A/S, where he was responsible for all aspects of pre-clinical and clinical drug development.
Peter holds a PhD in medicinal chemistry from the Royal Danish School of Pharmacy. He has also been a post doc with Yale University's department of organic chemistry.
Prior to joining Novo, Diana was a Business Development Manager at Chiesi where she was responsible for Orphan Diseases, Neonatology and Special care in-licensing and M&A. She also brings experience from working in the UK based biotech company hVIVO, where she was part of building an R&D division, including a fundraising and a company acquisition. Prior to this Diana worked in Healthcare Investment Banking in London.
Diana holds a PhD degree from University of Oxford in Radiation Oncology. She obtained her licentiate and undergraduate degree from Stockholm University and Karolinska Institute during which time she also worked as an IRTA at NIH, USA.
Søren joined Novo A/S in October 2011 as Managing Investment Director of Novo Seeds.
Søren obtained his MSc degree from the Technical University of Denmark in 1993 and his PhD degree in molecular biology in 1997 from the Technical University of Denmark. In addition, Søren has academic training as postdoctoral fellow at Stanford University School of Medicine.
Prior to joining Novo Seeds, Søren served as global manager of Bioinformatics and Genomics at Novozymes. Before Novozymes, Søren was CSO and Vice President of R&D at Exiqon A/S where he was responsible for development of microRNA based products for life science research, pharma services and diagnostics. Previously, Søren worked in cancer drug development as head of Lead Identification at BioImage and as research scientist at Novo Nordisk.
Søren serves on the Board of Directors of Affinicon, AMRA, Biosyntia, Reapplix A/S and RSPR Pharma. And since 2008, Søren has been board member of Danish Biotech (the Association of Biotechnology Industries in Denmark).
Mia joined Novo A/S in September 2016 as HR Senior Specialist in People & Organisation. She is responsible of legal compliance, salary & benefit, short- and long-term incentives and P&O processes, systems and tools.
Prior to joining Novo A/S, Mia was respectively HR Partner and HR Manager at Lett Law Firm in Copenhagen.
Mia holds an Master of Arts from the University of Copenhagen.
Lone joined Novo A/S in 2007. She is responsible for the coordination of the activities in People & Organisation.
Lone is educated in the banking sector, and has more than 25 years of experience in various administrative positions in the Novo Group, including responsibility for managing projects and budgets as well as the coordination of international meetings.
Dorrit is IT Manager in Novo A/S and the Novo Nordisk Foundation.
She is responsible for the IT strategy and execution, infrastructure, supplier management, IT projects, as well as the daily IT management and coordination.
Dorrit was responsible for the Novo A/S IT transition and domicile move, and now for the present IT setup.
She joined Novo A/S in 2008 and has 30 years experience from various IT positions in the Novo Group.
Dorrit is certified medical secretary, legal secretary and bi-lingual secretary. Furthermore, has a certificate in English for international business and trade, is certified IT instructor and has a master certificate as council guide in innovative leadership.
Jørgen joined Novo A/S as General Counsel in September 2012 and is responsible for all legal matters within the company, including contracts and compliance efforts.
Jørgen holds a Master of Laws from Århus University in 1993 and, furthermore, an LL.M. from King's College London in among other things Financing and International Trade Law. He is a member of the Danish Bar Association.
Prior to joining Novo A/S, Jørgen was Associate General Counsel with Novo Nordisk A/S, Corporate Legal for six years - the last three years as team lead in Licensing & Alliances. Before that, Jørgen worked as attorney in TDC A/S Legal Affairs for seven years with M&A and financing, and prior to that in private practice in a Copenhagen law firm for five years. Over the years, Jørgen has gained considerable experience within M&A, licensing, financing, litigation and arbitration, legal compliance and risk management.
Christian joined Novo A/S in October 2014 as Asset Director, Large Investments, taking part in managing and developing the growing portfolio of investments.
Prior to joining Novo, Christian was employed as a Principal in A.T. Kearney’s global health practice, working with strategy, M&A, and commercial & operational excellence across the MedTech & Pharmaceutical industries. Other previous employments include a position as Senior Vice President, Emerging Markets with Coloplast A/S.
Christian holds a MSc in Manufacturing from the Technical University of Denmark.
Michael has a broad knowledge of the health care business environment encompassing R&D as well as Marketing and Sales. Prior to joining Novo A/S he spent 15 years at Novo Nordisk where he held a number of international management positions with global responsibilities (V.P. International Marketing, Corporate VP Haemostasis and Chief Medical Officer BioPharm), European responsibility (V.P. of Haematology Business Unit, Zurich, Switzerland), and US responsibilities (V.P. BioPharm Business Unit (Princeton, USA). Most recently he served as Corporate V.P. Global Development, Clinical Operations Management at Novo Nordisk HQ. Michael is an MD, and holds an MBA.
Michael is a member of the Board of Directors of Orexo AB.
Eric joined Novo Ventures (US) Inc. in San Francisco, California in 2014. Prior to joining Novo Ventures (US) Inc., Eric was a Director at Apposite Capital where he established the firm’s San Francisco office and managed its secondary direct investment activity in the US. He has also worked for Vitapath Genetics in Business Development and Strategy, and as an Associate at Burrill & Company where he was a member of the firm’s venture capital practice. Before entering venture capital, Eric was a Leukemia & Lymphoma Society Post-Doctoral Fellow at UCLA. While conducting his post-doctoral research, he also spent time in the University’s technology transfer office.
Eric received a PhD in Molecular Biology from Princeton University, and a BA in Biophysics from Johns Hopkins University.
In April 2016, Christian joined Novo A/S as a Valuation Specialist. He is responsible for valuation matters, including supporting the deals teams in appraising potential investments and in exit considerations as well as monitoring the performances of portfolio companies.
Prior to joining Novo A/S, Christian was employed at PwC as Senior Manager in the Danish Deals team and obtained extensive expertise in valuation and financial modelling matters with respect to both an M&A context and regulatory purposes. During his time at PwC, Christian spent three years in the German Pharmaceutical & Life Sciences Valuation team, providing him with profound industry knowledge.
Christian holds a BSc in Economics and Business Administration and an MSc in Applied Economics and Finance from Copenhagen Business School.
Christoffer joined Novo A/S in February 2016 as Director, Large Investments, leading investment processes and taking part in managing and developing the growing portfolio of investments.
Prior to joining Novo A/S, Christoffer was a Senior Principal at BCG leading the Copenhagen Private Equity and Principal Investors practice area. Prior to joining BCG, Christoffer worked at Falck A/S as Global Head of Group Strategy and M&A, and most recently as CFO Falck Assistance. Prior to joining Falck, Christoffer worked as a Director at Carnegie Investment Banking focusing on buy-and sell-side M&A.
Christoffer holds a BSc in International Business and an MSc in Finance and Accounting from the Copenhagen Business School.
Fredrik joined Novo A/S in October 2016 as an Associate in Novo Large Investments. He participates in deal sourcing and execution as well as in managing and developing the growing portfolio of investments.
Prior to joining Novo A/S, Fredrik worked in the investment banking division at J.P. Morgan in London, advising clients in the European healthcare and financial services sectors on M&A transactions as well as equity and debt financings.
Fredrik holds a B.Sc. in Business and Economics and a M.Sc. in Intellectual Capital Management from the University of Gothenburg.
Previously, Christina served as Senior Business Development manager in Novozymes’ Business Creation and M&A division, focusing on identifying and building Novozymes' next growth platforms. Additionally, Christina has been working as associate patent agent at one of Europe’s largest patent and IP consulting firms, Zacco, and as technology analyst and consultant at the technology advisory firm, Lux Research Inc., advising both SMEs and Fortune500 on emerging technologies and scouting within the area of nanobiotechnology. Christina has also been serving as start-up mentor at Indiebio (CA) and Breakout Labs (CA).
Christina has a solid background in the field of nanobiotechnology and cancer drug discovery. She completed her post-doctoral training at the leading European cancer Centre, Institute Gustave Roussy /INSERM. Christina holds a PhD from University of California, Berkeley, and University of Copenhagen, and an MSc from the iNANO Centre at Aarhus University.
Mathias joined the Novo Ventures team as Associate in September 2016, where he will engage in deal flow activities and investment diligence as well as assist in portfolio management.
Mathias holds a PhD in Nanomedicine with an emphasis in Immunotherapy and Drug Delivery from Aarhus University (2016). During his education, Mathias has studied abroad at University of California Berkeley and Harvard Medical School. At Harvard, Mathias was associated with the Wyss Institute for Biological Inspired Engineering and Dana-Farber Cancer Institute.
Novo Ventures (US) Inc. is a separate legal entity that provides certain consultancy services to Novo A/S, mainly within the areas of identifying, analysing and negotiating various investment opportunities among life science and biotech companies in the US as well as certain follow-up activities related thereto, such as board memberships, financial control and reporting efforts.